hereditary angioedema

News

Hereditary Angioedema, FDA

FDA Approves Sebetralstat for Hereditary Angioedema

For the second time in under 3 weeks, the FDA has approved treatment for the inherited genetic disorder characterized by recurrent episodes of severe swelling.

PharmExec · 22h

FDA Approves KalVista Pharmaceuticals’ Ekterly for Hereditary Angioedema

Ekterly becomes the first FDA-approved oral on-demand treatment for hereditary angioedema in patients aged 12 years and older.

MPR · 18h

FDA Approves Oral Ekterly for On-Demand Hereditary Angioedema Treatment

The Food and Drug Administration (FDA) has approved Ekterly ® (sebetralstat) for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged 12 years and older.

The Manila Times32m

BioCryst to Highlight Patient-focused Research at the 2025 US HAEA National Summit

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present new findings from patient-focused ...

BioSpace1h

Second Half Milestones, KalVista’s Surprise Approval, Another RFK Jr. Lawsuit, More

H2 2025 catalysts to watch, biopharma implications of President Trump’s tax law, KalVista’s new hereditary angioedema drug that Marty Makary reportedly tried to reject, another lawsuit aimed at Health ...

Barchart on MSN19h

The Next Moderna? This Clinical-Stage Biotech Has Breakout Potential.

Moderna (MRNA), an undervalued name in the biotech space, rose to prominence during the COVID-19 pandemic. This occurred when ...

BMJ Case Reports2d

Hereditary angioedema in a paediatric patient presenting with abdominal pain and duodenal dilation

Hereditary angioedema (HAE) is a genetic disorder that causes sudden episodes of swelling, often accompanied by abdominal pain. Affecting roughly 1 in 50 000 people, HAE typically appears in childhood ...

BioSpace1d

KalVista Wins OK for First On-Demand Hereditary Angioedema Pill

Ekterly’s road to approval was not a smooth one. Last month, the FDA informed KalVista it would not meet its PDUFA date due ...

Orsini Selected as Specialty Pharmacy Partner for KalVista's EKTERLY® (sebetralstat)

Orsini, a leader in rare disease pharmacy solutions, has been chosen by KalVista Pharmaceuticals as a specialty pharmacy ...

Leading Factor Driving The Angioedema Treatment Market In 2025: Rise In Rare Disease Diagnoses Fueling The Growth

Angioedema Treatment Global Market Report 2025. The Business Research Company's Angioedema Treatment Global Market Report 2025 – Market Size, Trends, And ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results